Safety and Long-Term Patency of Endovascular Therapy for Infrarenal Aortic Disease: Single-Center Experience and Review of the Literature.

Autor:	Mangi MA, Meenakshisundaram C, Syed MA, Changal KH, Alyosif M, Burket MW; University of Toledo College of Medicine and Life Sciences, 3065 Arlington Avenue, Toledo, OH 43614 USA. mark.burket@utoledo.edu., Sheikh MA
Jazyk:	angličtina
Zdroj:	The Journal of invasive cardiology [J Invasive Cardiol] 2020 May; Vol. 32 (5), pp. 194-200.
DOI:	10.25270/jic/19.00413
Abstrakt:	Objectives: Endovascular therapy (EVT) has emerged as an alternative to surgery for the treatment of symptomatic infrarenal aortic stenosis (IAS). However, long-term outcomes with EVT are unknown. Methods: We performed a retrospective review of patients with IAS treated with the endovascular approach at the University of Toledo Medical Center, Toledo, Ohio. We compared our single-center study (SCS) with a review of published studies (ROS) regarding complications, patency rate (PR), and repeat intervention rate (RIR). Pearson's Chi-square or Fisher's exact test, and the Student's t-test or Mann-Whitney U-test, were used for categorical and continuous variables, respectively. For the ROS data, we used a pooled mean of means. Results: A total of 25 patients from the SCS were compared with 698 patients from the ROS data. Mean age was 63 years vs 58 years, females comprised 48% vs 54%, Rutherford class 3 comprised 68% vs 69%, and mean follow-up duration was 67 months vs 44 months in SCS vs ROS, respectively. PR at 12 months was 96% vs 90%, while PR at maximum time-period was 92% vs 76% in SCS vs ROS, respectively. RIR in SCS was 4% at 12 months and 8% at the maximum time period (20.2 years). RIR in ROS was 24% at the maximum time period (10 years). The mortality rate was 0% in the SCS arm vs 3.4% in the ROS arm. Conclusion: EVT is highly effective and safe, and was associated with excellent patency rates at long-term follow-up.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu